申请人:NRL Pharma, Inc.
公开号:EP1762558A1
公开(公告)日:2007-03-14
The present invention has an object to develop novel compounds which are effective for the therapy of syndrome X, cancer, myxedema, vascular chronic inflammation and the like, and furthermore prevent/treat the restenosis caused in an artery expansion by a balloon or a stent and have the activity facilitating regenerative medicine by inhibiting rejection of own cells or tissues to be transplanted and the method for preparing the same. Novel acetal derivatives obtained by acylating the hydroxyl group at the 2-position of the orcylaldehyde which ascochlorin and its analogs have and thereafter bonding an alcohol to the aldehyde group in the presence of a basic catalyst are found to achieve the object.
本发明的目的是开发新的化合物,用于治疗综合征X、癌症、黏液水肿、血管慢性炎症等疾病,并能够预防/治疗由气球或支架扩张引起的动脉再狭窄,并通过抑制自体细胞或组织的排斥作用促进再生医学的活性,以及其制备方法。通过在基本催化剂的存在下,酰化ascochlorin及其类似物具有的orcylaldehyde的2位羟基,并在醛基上结合醇,得到新的缩醛衍生物,发现可以实现该目的。